ACAD241220C23000
- 0.05
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $32
ACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy Rating
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $32
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $32
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $18 to $39
ACADIA Pharmaceuticals: Strong Buy Rating Backed by Promising Growth and Undervalued Assets
Stifel Nicolaus Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $20 to $39
ACADIA Pharmaceuticals Analyst Ratings
Buy Rating for ACADIA Pharmaceuticals Amid Strong Financial Performance and Growth Prospects
Guggenheim Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $20
Raymond James Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating
ACADIA Pharmaceuticals Analyst Ratings
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $31
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $20
Assessing ACADIA Pharmaceuticals Amidst Leadership Transition and Pipeline Prospects: A Hold Rating Recommendation
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and ACADIA Pharmaceuticals (ACAD)